[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100640689":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":18,"centralContacts":25,"locations":18,"responsibleParty":31,"collaborators":18,"id":33,"slug":34,"hasResults":35,"nctId":36,"briefTitle":37,"officialTitle":38,"acronym":18,"eligibilityCriteria":39,"healthyVolunteers":35,"sex":40,"minAge":41,"maxAge":18,"enrollmentInfo":42,"targetDuration":18,"studyType":45,"phases":46,"briefSummary":48,"conditions":49,"keywords":18,"overallStatus":51,"whyStopped":18,"lastUpdateSubmitDate":52,"lastUpdatePostDateStruct":53,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":18},{"fullName":5,"class":6},"Institute of Hematology & Blood Diseases Hospital, China","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Intervention group","EXPERIMENTAL","For patients in the intervention group, the daGOAT model will be used to predict the occurrence of severe acute GvHD from day 17 to day 23 after transplantation. Each subject will be stratified into low-, intermediate-, and high-risk groups, and corresponding preventive interventions were implemented according to their risk levels.",[13],"Drug: Ruxolitinib",{"label":15,"type":16,"description":17,"interventionNames":18},"Control group","NO_INTERVENTION","For patients in the control group, they will receive standard prophylaxis without additional GvHD prophylactic agents, including mesenchymal cell infusion, anti-CD25 monoclonal antibodies, and ruxolitinib outside the scope specified in the study protocol.",null,[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":18},"DRUG","Ruxolitinib","1. Model-predicted high-risk patients: will receive standard prophylaxis plus ruxolitinib 5mg twice daily (bid) orally until at least day 60 post-transplantion and will be terminated after day 100. If severe hematological signs occur such as when there is severe neutropenia (\\\u003C0.1×10\\^9\u002FL), ruxolitinib can be used at half dose or discontinued until recovery.\n2. Model-predicted moderate-risk patients: will receive standard prophylaxis plus ruxolitinib 5mg once daily (qd) orally until at least day 60 post-transplantion and will be terminated after day 100. If severe hematological signs occur such as when there is severe neutropenia (\\\u003C0.1×10\\^9\u002FL), ruxolitinib can be used at half dose or discontinued until recovery.\n3. Model-predicted low-risk patients: will receive standard prophylaxis without additional GvHD prophylactic agents, including mesenchymal cell infusion, anti-CD25 monoclonal antibodies, and ruxolitinib outside the scope specified in the study protocol.",[9],[26],{"name":27,"role":28,"phone":29,"phoneExt":18,"email":30},"Yahui Feng","CONTACT","022-23608045","fengyahui@ihcams.ac.cn",{"type":32,"investigatorFullName":18,"investigatorTitle":18,"investigatorAffiliation":18,"oldNameTitle":18,"oldOrganization":18},"SPONSOR","100640689","phase-3-dagoat-guided-prevention-of-severe-agvhd-after-allo-hsct-100640689",false,"NCT07588945","daGOAT-Guided Prevention of Severe aGVHD After Allo-HSCT","A Multicenter Randomized Controlled Trial of daGOAT Model-guided Prevention of Severe Acute Graft-versus-host Disease in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation","Inclusion Criteria:\n\n1. Age \\> 16 years old.\n2. HLA-haploidentical transplant.\n3. Able to take oral medications.\n4. Patients must provide written informed consent before the start of the study procedures.\n\nExclusion Criteria:\n\n1. Patients who have undergone tandem transplantation or multiple transplantations.\n2. Patients who are allergic to or cannot tolerate ruxolitinib.\n3. Patients with mental or other medical conditions that make them unable to comply with the study treatment and monitoring requirements.\n4. Patients who are ineligible for the study due to other factors, or who will bear great risk if they participate in the study.","ALL","16 Years",{"count":43,"type":44},438,"ESTIMATED","INTERVENTIONAL",[47],"PHASE3","This study aims to evaluate the efficacy of prophylactic ruxolitinib in adult patients at intermediate-to-high risk of severe acute GvHD, as predicted by the daGOAT model.",[50],"Transplant-Related Disorder","NOT_YET_RECRUITING","2026-05-10",{"date":54,"type":55},"2026-05-15","ACTUAL",{"date":57,"type":44},"2026-06-01",{"date":59,"type":44},"2028-06-01",{"name":5,"class":6}]